Vincenzo Di Marzo

Vincenzo Di Marzo's AcademicInfluence.com Rankings

Vincenzo Di Marzo

Chemistry

#898

World Rank

#1465

Historical Rank

Organic Chemistry

#85

World Rank

#118

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Vincenzo Di Marzo's Degrees

PhD Chemistry University of Naples Federico II
Masters Chemistry University of Naples Federico II
Bachelors Chemistry University of Naples Federico II

Why Is Vincenzo Di Marzo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Vincenzo Di Marzo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide (1999) (2126)
The endogenous cannabinoid system controls extinction of aversive memories (2002) (1659)
Leptin-regulated endocannabinoids are involved in maintaining food intake (2001) (1556)
Formation and inactivation of endogenous cannabinoid anandamide in central neurons (1994) (1548)
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (2010) (1504)
Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors (2005) (1434)
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity (2003) (1134)
The endocannabinoid system and its therapeutic exploitation (2004) (989)
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors (2002) (981)
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain (2003) (975)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide (2001) (964)
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (2014) (763)
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol (2002) (760)
Endocannabinoid control of food intake and energy balance (2005) (708)
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. (2009) (691)
Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes (2011) (690)
Targeting the endocannabinoid system: to enhance or reduce? (2008) (686)
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action (1998) (684)
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. (2006) (652)
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. (2001) (547)
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. (1998) (513)
Endocannabinoid signaling at the periphery: 50 years after THC. (2015) (498)
The endocannabinoid system: a general view and latest additions (2004) (485)
Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma (2006) (462)
Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain (2006) (460)
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. (2013) (429)
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. (1998) (416)
Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review (2015) (397)
Cannabinoids and the expanded endocannabinoid system in neurological disorders (2019) (391)
Endocannabinoids control spasticity in a multiple sclerosis model (2001) (377)
Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men (2007) (374)
Biochemistry and pharmacology of endovanilloids. (2007) (374)
Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice (2000) (373)
Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes* (1997) (369)
N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. (2000) (363)
Endocannabinoids and the control of energy balance (2007) (360)
The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism* (2001) (359)
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity (2000) (349)
Intense exercise increases circulating endocannabinoid and BDNF levels in humans—Possible implications for reward and depression (2012) (343)
N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia* (2003) (331)
Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain* (2001) (322)
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease (2000) (321)
Endocannabinoids and the regulation of their levels in health and disease (2007) (316)
Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. (1999) (311)
Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. (1999) (310)
Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. (2004) (302)
Possible endocannabinoid control of colorectal cancer growth. (2003) (293)
From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. (2016) (289)
Endocannabinoid signalling and the deteriorating brain (2014) (286)
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine (2002) (282)
Elevation of Endocannabinoid Levels in the Ventrolateral Periaqueductal Grey through Inhibition of Fatty Acid Amide Hydrolase Affects Descending Nociceptive Pathways via Both Cannabinoid Receptor Type 1 and Transient Receptor Potential Vanilloid Type-1 Receptors (2006) (281)
Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. (2014) (281)
Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8 (2008) (278)
Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning (2008) (269)
Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. (1997) (269)
Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System (2007) (264)
Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period (1999) (263)
Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. (2008) (262)
Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. (2016) (261)
Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation (2001) (259)
Endovanilloid signaling in pain (2002) (258)
Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors (2003) (254)
Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa (2005) (253)
Endocannabinoid signalling in the blood of patients with schizophrenia (2003) (250)
Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets (2001) (248)
‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance (1998) (246)
Prefrontal Cortex Stimulation Induces 2-Arachidonoyl-Glycerol-Mediated Suppression of Excitation in Dopamine Neurons (2004) (245)
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. (2000) (244)
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation (2012) (240)
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? (1999) (239)
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474 (2017) (237)
Anandamide: some like it hot. (2001) (235)
Structure‐activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens (2001) (233)
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels (2005) (230)
The Endocannabinoid System and its Modulation by Phytocannabinoids (2015) (226)
Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. (2009) (224)
The endocannabinoid signalling system: Biochemical aspects (2005) (217)
Mechanisms of the Anti-Obesity Effects of Oxytocin in Diet-Induced Obese Rats (2011) (216)
Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity (2017) (216)
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats (2007) (216)
The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations (2017) (214)
Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels (2006) (213)
The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation (2009) (212)
The vanilloid receptor (VR1)‐mediated effects of anandamide are potently enhanced by the cAMP‐dependent protein kinase (2001) (212)
Cannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes (2006) (210)
New perspectives on enigmatic vanilloid receptors (2000) (210)
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. (2013) (209)
Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors (2001) (203)
Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. (1996) (203)
Exogenous Anandamide Protects Rat Brain against Acute Neuronal Injury In Vivo (2001) (202)
The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. (1998) (202)
Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High‐fat Diet (2008) (199)
Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice (2018) (197)
Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide* (2000) (194)
Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. (2001) (194)
Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels (2009) (192)
A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease (2005) (191)
Endocannabinoids as physiological regulators of colonic propulsion in mice. (2002) (191)
Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis (2003) (191)
The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. (2009) (190)
Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. (2007) (190)
Analgesic actions of N‐arachidonoyl‐serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors (2007) (190)
Anandamide receptors. (2002) (188)
Endocannabinoid system and mood disorders: priming a target for new therapies. (2013) (187)
Cannabinoid receptors and their role in neuroprotection (2007) (186)
Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma ‘anandamide amidohydrolase’ (1995) (184)
Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. (2000) (183)
New approaches and challenges to targeting the endocannabinoid system (2018) (181)
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. (1999) (181)
Presence and regulation of the endocannabinoid system in human dendritic cells. (2002) (180)
The endocannabinoid system in obesity and type 2 diabetes (2008) (180)
Why do cannabinoid receptors have more than one endogenous ligand (2012) (180)
Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. (2002) (178)
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. (2010) (177)
Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil against In Vivo Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases (2003) (176)
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders (2003) (176)
Involvement of the cAMP/protein kinase A pathway and of mitogen‐activated protein kinase in the anti‐proliferative effects of anandamide in human breast cancer cells (1999) (174)
Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. (2000) (174)
Plant, synthetic, and endogenous cannabinoids in medicine. (2006) (174)
Targeting the endocannabinoid system in cancer therapy: A call for further research (2002) (172)
Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. (1998) (172)
Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors (2009) (172)
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling (2008) (172)
Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels (2010) (171)
Anandamide may mediate sleep induction (1997) (170)
Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. (2004) (170)
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. (2012) (169)
Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. (2000) (169)
Endocannabinoids: synthesis and degradation. (2008) (169)
Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9‐Tetrahydrocannabinol‐Tolerant Rats (2000) (166)
Anandamide inhibits adhesion and migration of breast cancer cells. (2006) (165)
Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets (2008) (165)
The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. (2001) (164)
Non‐THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro‐apoptotic effects and underlying mechanisms (2013) (163)
N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating both Cannabinoid and Vanilloid Receptors (2007) (161)
Tonic Endovanilloid Facilitation of Glutamate Release in Brainstem Descending Antinociceptive Pathways (2007) (160)
Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response (1999) (160)
Phosphatidic Acid as the Biosynthetic Precursor of the Endocannabinoid 2‐Arachidonoylglycerol in Intact Mouse Neuroblastoma Cells Stimulated with Ionomycin (1999) (159)
The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation (2009) (158)
Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. (2001) (157)
Control by the endogenous cannabinoid system of ras oncogene‐dependent tumor growth (2001) (156)
Phytocannabinoids beyond the Cannabis plant – do they exist? (2010) (156)
Interactions between synthetic vanilloids and the endogenous cannabinoid system (1998) (155)
Evolutionary origins of the endocannabinoid system. (2006) (155)
Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c‐Fos expression in the hypothalamus (2007) (153)
Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake (2006) (153)
Endocannabinoids: synthesis and degradation. (2006) (153)
A new strategy to block tumor growth by inhibiting endocannabinoid inactivation (2004) (152)
Novel selective and metabolically stable inhibitors of anandamide cellular uptake. (2003) (151)
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re‐feeding (2009) (151)
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. (2003) (148)
An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? (2011) (148)
The biosynthesis, fate and pharmacological properties of endocannabinoids. (2005) (147)
Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. (1995) (146)
Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism (2004) (146)
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis (2009) (146)
TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. (2008) (145)
Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex (2015) (145)
Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response (2003) (143)
Further evidence for the existence of a specific process for the membrane transport of anandamide. (2004) (143)
Endocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent Rats (2012) (141)
Non‐psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action (2011) (141)
Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. (2010) (141)
At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. (2012) (140)
Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. (1999) (140)
An introduction to the endocannabinoid system: from the early to the latest concepts (2009) (140)
Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. (2007) (140)
Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer (2012) (139)
Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications (2006) (139)
Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti‐inflammatory agent (2015) (139)
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. (2006) (138)
Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice (2006) (136)
Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. (2001) (136)
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis (2005) (136)
The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. (2009) (136)
Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. (2001) (135)
Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice (2011) (135)
Depolarization‐induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2‐arachidonoylglycerol (2006) (135)
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. (2010) (135)
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. (2003) (134)
Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies (2005) (134)
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease (2003) (129)
Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy (2010) (129)
Biochemistry of the Endogenous Ligands of Cannabinoid Receptors (1998) (128)
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. (2005) (128)
Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain (2004) (128)
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis (2005) (128)
Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. (2011) (127)
Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. (2012) (127)
Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System (2014) (127)
Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. (2003) (127)
Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation1. (2000) (126)
Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy (2011) (126)
CB1 antagonists for obesity—what lessons have we learned from rimonabant? (2009) (125)
Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues (2002) (125)
Acute neuronal injury, excitotoxicity, and the endocannabinoid system (2002) (125)
Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret (2007) (124)
Up‐regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation (2006) (124)
Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. (1999) (123)
Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria. (2015) (122)
Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis (2005) (122)
New approaches and challenges to targeting the endocannabinoid system (2018) (122)
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. (2001) (121)
Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons (2013) (121)
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. (2006) (121)
An introduction to the endocannabinoid system: from the early to the latest concepts. (2009) (120)
The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis (2009) (120)
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis (2013) (118)
Inhibitory effect of cannabichromene, a major non‐psychotropic cannabinoid extracted from Cannabis sativa, on inflammation‐induced hypermotility in mice (2012) (117)
Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight (2010) (117)
Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. (1997) (117)
'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. (1998) (117)
Endocannabinoid overactivity and intestinal inflammation (2006) (115)
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon (2007) (115)
Comparative biology of the endocannabinoid system (2000) (114)
Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. (2009) (114)
Protective role of palmitoylethanolamide in contact allergic dermatitis (2009) (113)
Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. (2007) (113)
Trick or treat from food endocannabinoids? (1998) (113)
Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. (2001) (112)
The endocannabinoid system is modulated in response to spinal cord injury in rats (2009) (110)
Neural precursor cells induce cell death of high-grade astrocytomas via stimulation of TRPV1 (2012) (109)
The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice (2010) (109)
Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain (2008) (109)
Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. (2000) (108)
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice (2001) (108)
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. (2002) (108)
Finding of endocannabinoids in human eye tissues: implications for glaucoma. (2005) (107)
Actions of two naturally occurring saturated N‐acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels (2004) (107)
The anti‐inflammatory mediator palmitoylethanolamide enhances the levels of 2‐arachidonoyl‐glycerol and potentiates its actions at TRPV1 cation channels (2016) (106)
Novel bioactive metabolites of dipyrone (metamizol). (2012) (106)
The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high‐fat diet (2008) (105)
Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide (2008) (105)
Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability (2012) (104)
Endocannabinoids and energy homeostasis: An update (2014) (103)
Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. (2008) (102)
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. (2011) (101)
Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice (2015) (101)
Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β‐cells (2007) (100)
Protective activation of the endocannabinoid system during ischemia in dopamine neurons (2006) (100)
FAAH and anandamide: is 2-AG really the odd one out? (2008) (99)
Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. (1996) (99)
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. (2004) (98)
The endocannabinoid system and the molecular basis of paralytic ileus in mice (2002) (97)
Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects (2011) (95)
Human lung‐resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors (2016) (93)
Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis (2018) (93)
Identification of Endocannabinoids and Cannabinoid CB1 Receptor mRNA in the Pituitary Gland (1999) (93)
Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine (2004) (92)
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease (2001) (92)
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. (2004) (92)
Identification of Endocannabinoids and Related Compounds in Human Fat Cells (2007) (91)
Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide (2011) (91)
Cannabinoid receptors are absent in insects (2001) (91)
Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. (1998) (90)
TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception. (2012) (90)
TRPV1 channels control synaptic plasticity in the developing superior colliculus (2009) (89)
Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems (2002) (88)
An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse (2016) (88)
Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy (2013) (88)
Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis (2019) (88)
Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. (2013) (87)
Endocannabinoids: A unique opportunity to develop multitarget analgesics (2013) (87)
An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis (2010) (87)
Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. (1997) (86)
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity (2013) (86)
Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism (2013) (86)
The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats (2011) (85)
Why do cannabinoid receptors have more than one endogenous ligand? (2012) (85)
A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. (2002) (85)
Endocannabinoids in nervous system health and disease: the big picture in a nutshell (2012) (84)
Chronic Morphine Modulates the Contents of the Endocannabinoid, 2-Arachidonoyl Glycerol, in Rat Brain (2003) (83)
Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor (2017) (83)
Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients (2010) (83)
Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy. (2012) (83)
Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis‐induced hypermotility: cross‐talk between κ‐opioid and cannabinoid CB1 receptors (2008) (82)
The A1 adenosine receptor as a new player in microglia physiology (2014) (82)
Gender‐dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system (2008) (82)
The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. (2012) (82)
Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. (2000) (82)
Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders (2012) (82)
Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. (2009) (81)
Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. (2010) (81)
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. (2005) (81)
Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. (2006) (81)
Targeting the endocannabinoid system: to enhance or reduce? (2008) (80)
Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle (2011) (80)
Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease (2008) (80)
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. (2002) (80)
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. (2008) (79)
The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. (2009) (79)
Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats (2010) (79)
From endocannabinoid profiling to 'endocannabinoid therapeutics'. (2009) (78)
Endocannabinoid metabolic pathways and enzymes. (2005) (78)
Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. (1995) (78)
Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome (2017) (78)
Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. (2007) (77)
Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. (2010) (77)
Changes in endocannabinoid contents in reward‐related brain regions of alcohol‐exposed rats, and their possible relevance to alcohol relapse (2004) (77)
Opposing Control of Cannabinoid Receptor Stimulation on Amyloid-β-Induced Reactive Gliosis: In Vitro and in Vivo Evidence (2007) (77)
The endocannabinoid system in obesity and type 2 diabetes. (2008) (77)
CB1 receptor antagonism: biological basis for metabolic effects (2008) (76)
Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system (2006) (76)
The Endocannabinoid 2-Arachidonoylglycerol Is Responsible for the Slow Self-Inhibition in Neocortical Interneurons (2008) (76)
2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons (2015) (76)
Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P (2006) (75)
Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. (2005) (75)
Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. (2009) (74)
Palmitoylethanolamide normalizes intestinal motility in a model of post‐inflammatory accelerated transit: involvement of CB1 receptors and TRPV1 channels (2014) (74)
Circulating and hepatic endocannabinoids and endocannabinoid‐related molecules in patients with cirrhosis (2009) (74)
A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats (2006) (74)
"Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control. (2012) (73)
Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome (2019) (73)
Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. (2009) (73)
The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG (2013) (73)
Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels (2010) (73)
Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. (2001) (72)
Development of the First Ultra-Potent “Capsaicinoid” Agonist at Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channels and Its Therapeutic Potential (2005) (72)
The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. (2010) (72)
A Gradient of 2-Arachidonoylglycerol Regulates Mouse Epididymal Sperm Cell Start-Up1 (2010) (72)
Endocannabinoids : The Brain and Body's Marijuana and Beyond (2005) (72)
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis (2006) (72)
Forebrain-Specific Inactivation of Gq/G11 Family G Proteins Results in Age-Dependent Epilepsy and Impaired Endocannabinoid Formation (2006) (71)
The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. (2008) (71)
The endocannabinoid system mediates aerobic exercise-induced antinociception in rats (2014) (71)
Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men (2013) (70)
Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain (2020) (70)
The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels (2014) (69)
Development of an activity-based probe and in silico design reveal highly selective inhibitors for diacylglycerol lipase-α in brain. (2013) (69)
Spinal anandamide produces analgesia in neuropathic rats: Possible CB1- and TRPV1-mediated mechanisms (2012) (69)
A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. (2006) (69)
Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. (1995) (69)
Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. (1998) (68)
Periaqueductal gray metabotropic glutamate receptor subtype 7 and 8 mediate opposite effects on amino acid release, rostral ventromedial medulla cell activities, and thermal nociception. (2007) (67)
Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice (2008) (67)
Altered endocannabinoid signalling after a high-fat diet in Apoe−/− mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance (2011) (67)
Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling (2016) (66)
The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. (2014) (66)
Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. (2005) (66)
Cannabimimetic fatty acid derivatives in cancer and inflammation. (2000) (66)
Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. (2012) (66)
Maternal dietary fat determines metabolic profile and the magnitude of endocannabinoid inhibition of the stress response in neonatal rat offspring. (2010) (66)
Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. (2007) (66)
At the Tip of an Iceberg: Prenatal Marijuana and Its Possible Relation to Neuropsychiatric Outcome in the Offspring (2016) (65)
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats (2007) (65)
A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2‐arachidonoylglycerol with potential anti‐obesity effects (2013) (64)
Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. (2015) (64)
Anandamide as an intracellular messenger regulating ion channel activity (2005) (64)
Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel TRPV1 and TRPA1 modulators. (2012) (64)
Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa). (2011) (63)
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. (1997) (63)
Basal and Fasting/Refeeding‐regulated Tissue Levels of Endogenous PPAR‐α Ligands in Zucker Rats (2010) (63)
CB1 Cannabinoid Receptors Couple to Focal Adhesion Kinase to Control Insulin Release* (2013) (63)
Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp (2010) (62)
Evidence for an endocannabinoid system in the central nervous system of the leech Hirudo medicinalis. (2001) (62)
Anti‐inflammatory Effect of Palmitoylethanolamide on Human Adipocytes (2009) (62)
Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. (2008) (62)
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. (2007) (62)
The effect of cannabichromene on adult neural stem/progenitor cells (2013) (62)
The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. (2010) (61)
Bisphenol A Induces Fatty Liver by an Endocannabinoid-Mediated Positive Feedback Loop. (2016) (61)
Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. (1999) (61)
A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. (2004) (61)
Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. (2004) (61)
Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. (2008) (60)
New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. (2007) (60)
The 1,2,3-triazole ring as a peptido- and olefinomimetic element: discovery of click vanilloids and cannabinoids. (2007) (60)
Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists (2003) (60)
The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity (2012) (59)
Endocannabinoids Link Feeding State and Auditory Perception-Related Gene Expression (2004) (59)
The Endocannabinoid System Protects Rat Glioma Cells Against HIV-1 Tat Protein-induced Cytotoxicity (2002) (59)
Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. (2010) (59)
Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. (2008) (59)
Metabolism of anandamide and 2-arachidonoylglycerol: An historical overview and some recent developments (2007) (59)
Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. (2016) (58)
Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. (2012) (58)
Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels (2014) (58)
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis (2015) (57)
Endocannabinoids and neuropathic pain: focus on neuron–glia and endocannabinoid–neurotrophin interactions (2014) (57)
Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. (2012) (56)
Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB1R signaling and anxiety‐like behavior (2015) (56)
Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. (2003) (55)
The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. (2011) (55)
Indole-2-carboxamides as allosteric modulators of the cannabinoid CB₁ receptor. (2012) (55)
Anandamide as an intracellular messenger regulating ion channel activity. (2005) (55)
The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. (2002) (55)
Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. (2010) (54)
Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. (2007) (54)
A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. (2006) (53)
Rimonabant Precipitates Anxiety in Rats Withdrawn from Palatable Food: Role of the Central Amygdala (2013) (53)
Endocannabinoid chemical biology: a tool for the development of novel therapies. (2009) (53)
Acute inhibition of diacylglycerol lipase blocks endocannabinoid‐mediated retrograde signalling: evidence for on‐demand biosynthesis of 2‐arachidonoylglycerol (2013) (53)
The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats (2008) (53)
The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. (2005) (52)
Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. (2006) (52)
Taste-guided identification of high potency TRPA1 agonists from Perilla frutescens. (2009) (52)
The effects of anandamide on memory consolidation in mice involve both D1and D2 dopamine receptors (1997) (52)
Functional interaction between TRPV1 and mu-opioid receptors in the descending antinociceptive pathway activates glutamate transmission and induces analgesia. (2009) (51)
Selection of alternative G-mediated signaling pathways at the dopamine D2 receptor by protein kinase C (1993) (51)
Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation (2016) (51)
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. (2016) (51)
Obesity Affects the Microbiota–Gut–Brain Axis and the Regulation Thereof by Endocannabinoids and Related Mediators (2020) (51)
Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons. (2015) (51)
Occurrence and possible biological role of the endocannabinoid system in the sea squirt Ciona intestinalis (2005) (50)
Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. (2011) (50)
2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. (2012) (50)
The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization (2008) (50)
Comparative biology of the endocannabinoid system possible role in the immune response. (2000) (50)
The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus (2008) (50)
Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach. (2019) (49)
Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis (2017) (49)
Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. (1995) (49)
Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin (2008) (49)
Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity (2016) (49)
Cannabinoid properties of methylfluorophosphonate analogs. (2000) (49)
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia (2019) (49)
N-Acylvanillamides: development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor. (2002) (49)
Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. (2010) (48)
Acute Resistance Exercise Induces Antinociception by Activation of the Endocannabinoid System in Rats (2014) (48)
The Endocannabinoid 2-Arachidonoyl-Glycerol Controls Odor Sensitivity in Larvae of Xenopus laevis (2010) (48)
Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. (2014) (48)
Role of endocannabinoids and endovanilloids in Ca2+ signalling. (2009) (48)
Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect (2018) (47)
Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. (2011) (47)
Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro (2007) (47)
Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling. (2020) (47)
Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. (2010) (47)
Role of endocannabinoids and endovanilloids in Ca2+ signalling. (2009) (47)
Endocannabinoids: Some Like it Fat (and Sweet Too) (2008) (47)
Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats (2008) (47)
Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. (2011) (47)
The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. (2019) (46)
Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study (2014) (46)
Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. (2016) (46)
Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous vegetables (Brassicaceae): evidence for TRPA1‐independent effects (2012) (46)
Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: Insulin and melanocortins (2008) (46)
Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew (2005) (46)
Effects of non‐euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice (2018) (45)
Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB₁ receptor ligand. (2012) (45)
Anandamide-derived Prostamide F2α Negatively Regulates Adipogenesis (2013) (45)
The Developmentally Regulated Avian Ch21 Lipocalin Is an Extracellular Fatty Acid-binding Protein* (1996) (45)
The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus (2019) (45)
Possible Anandamide and Palmitoylethanolamide involvement in human stroke (2010) (45)
Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. (2003) (44)
DAG Lipase Involvement in Depolarization-Induced Suppression of Inhibition: Does Endocannabinoid Biosynthesis Always Meet the Demand? (2010) (44)
Negative Regulation of Leptin-induced Reactive Oxygen Species (ROS) Formation by Cannabinoid CB1 Receptor Activation in Hypothalamic Neurons (2015) (44)
Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems (2009) (44)
Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. (2005) (43)
2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation (2017) (43)
Endocannabinoids and related fatty acid amides, and their regulation, in the salivary glands of the lone star tick. (2003) (43)
Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. (2010) (43)
Why endocannabinoids are not all alike (2008) (43)
Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis (2006) (42)
Diacylglycerol Lipase Is Not Involved in Depolarization-Induced Suppression of Inhibition at Unitary Inhibitory Connections in Mouse Hippocampus (2010) (42)
Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats. (2013) (42)
Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. (2005) (42)
Chronic exposure to cannabinoids during adolescence causes long‐lasting behavioral deficits in adult mice (2016) (42)
CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides (2014) (42)
Orexin-A and Endocannabinoid Activation of the Descending Antinociceptive Pathway Underlies Altered Pain Perception in Leptin Signaling Deficiency (2016) (41)
A TRPV1‐to‐secretagogin regulatory axis controls pancreatic β‐cell survival by modulating protein turnover (2017) (40)
N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. (2011) (40)
Abstract 215: Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. (2013) (40)
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold. (2012) (40)
Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture (2015) (40)
Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis (2014) (39)
Platelet-rich plasma exerts antinociceptive activity by a peripheral endocannabinoid-related mechanism. (2013) (39)
The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain (2008) (39)
Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy (2017) (39)
A re‐evaluation of 9‐HODE activity at TRPV1 channels in comparison with anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons (2012) (38)
CB(1) receptor antagonism: biological basis for metabolic effects. (2008) (38)
Effect of maternal under-nutrition on pup body weight and hypothalamic endocannabinoid levels (2003) (38)
Endocannabinoids Generated by Ca2+ or by Metabotropic Glutamate Receptors Appear to Arise from Different Pools of Diacylglycerol Lipase (2011) (38)
Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat (2020) (38)
Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in vitro. (1995) (38)
Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders (2015) (38)
Aquatic invertebrates open up new perspectives in eicosanoid research: biosynthesis and bioactivity. (1994) (37)
Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline. (2015) (37)
The gut microbiome, endocannabinoids and metabolic disorders. (2020) (37)
Cannabinomimetic lipid from a marine cyanobacterium. (2011) (37)
Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists. (2009) (36)
Exploiting Nanotechnologies and TRPV1 Channels to Investigate the Putative Anandamide Membrane Transporter (2010) (36)
Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB1 receptors: a keratinocyte-dependent effect (2011) (36)
Brain TRPV1: a depressing TR(i)P down memory lane? (2008) (36)
Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy (2015) (36)
Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non‐cannabinoid receptor‐mediated mechanisms (2008) (36)
Anandamide and AM251, via water, modulate food intake at central and peripheral level in fish. (2010) (36)
Taste sensitivity to 6-n-propylthiouracil is associated with endocannabinoid plasma levels in normal-weight individuals. (2013) (36)
Rapid and Concomitant Gut Microbiota and Endocannabinoidome Response to Diet-Induced Obesity in Mice (2019) (36)
Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. (2015) (35)
Non-psychotropic analgesic drugs from the endocannabinoid system: "magic bullet" or "multiple-target" strategies? (2013) (35)
The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease? (2012) (35)
Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice (2019) (35)
The endocannabinoid system in renal cells: regulation of Na+ transport by CB1 receptors through distinct cell signalling pathways (2015) (35)
Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor. (2011) (35)
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease (2005) (35)
Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPARα Agonists (2021) (34)
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors (2013) (34)
CB1 receptor activation induces intracellular Ca2+ mobilization and 2-arachidonoylglycerol release in rodent spinal cord astrocytes (2018) (34)
A novel multifunctional metabolic pathway in a marine mollusc leads to unprecedented prostaglandin derivatives (prostaglandin 1,15-lactones). (1991) (33)
Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. (2012) (33)
Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation (2015) (33)
Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy (2018) (33)
Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults (2015) (33)
[The endocannabinoid system as a target for the development of new drugs for cancer therapy]. (2003) (33)
Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. (2015) (32)
Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity (2019) (32)
Biosynthesis, structure and biological activity of hydroxyeicosatetraenoic acids in Hydra vulgaris. (1993) (32)
Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse (2017) (32)
Participants with Normal Weight or with Obesity Show Different Relationships of 6-n-Propylthiouracil (PROP) Taster Status with BMI and Plasma Endocannabinoids (2017) (32)
Dose‐Specific Effects of Di‐Isononyl Phthalate on the Endocannabinoid System and on Liver of Female Zebrafish (2017) (32)
Minor Bioactive Polyacetylenes from Petrosia ficiformis (1990) (32)
Ultra-micronized palmitoylethanolamide rescues the cognitive decline-associated loss of neural plasticity in the neuropathic mouse entorhinal cortex-dentate gyrus pathway (2019) (32)
High molecular weight polyacetylenes from Petrosia ficiformis: Further structural analysis and biological activity (1989) (31)
Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. (2009) (31)
Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women With Endometriosis (2016) (31)
Participation of Prostaglandin E2 in Dopamine D2 Receptor‐Dependent Potentiation of Arachidonic Acid Release (1992) (31)
Oxidative metabolism of lipoamino acids and vanilloids by lipoxygenases and cyclooxygenases. (2007) (31)
New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity. (2015) (31)
Discovery of glycine sulfonamides as dual inhibitors of sn-1-diacylglycerol lipase α and α/β-hydrolase domain 6. (2014) (31)
Endocannabinoids, feeding and suckling – from our perspective (2006) (30)
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. (2011) (30)
3-Ylidenephthalides as a new class of transient receptor potential channel TRPA1 and TRPM8 modulators. (2013) (30)
Polypharmacology Shakes Hands with Complex Aetiopathology. (2015) (30)
(-)-Menthylamine derivatives as potent and selective antagonists of transient receptor potential melastatin type-8 (TRPM8) channels. (2010) (30)
Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. (2020) (29)
N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice (2019) (29)
Disruption of the gonadal endocannabinoid system in zebrafish exposed to diisononyl phthalate. (2018) (29)
Effects of curcumin and curcumin analogues on TRP channels. (2017) (29)
New tetrazole-based selective anandamide uptake inhibitors. (2008) (29)
Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation (2011) (28)
α-and γ-Pyrone-poly·propionates from the mediterranean ascoglossan mollusc ercolania funerea (1992) (28)
Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all (2012) (28)
Anandamide serves two masters in the brain (2010) (28)
Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. (2013) (28)
Polymorphism rs1761667 in the CD36 Gene Is Associated to Changes in Fatty Acid Metabolism and Circulating Endocannabinoid Levels Distinctively in Normal Weight and Obese Subjects (2017) (27)
Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: interactions with muscarinic and delta-opioid receptors. (2009) (27)
Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties. (2019) (27)
Chemical characterisation of oxidative degradation products of Δ9-THC (2010) (27)
Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture (2015) (27)
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. (2016) (27)
Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists. (2012) (27)
The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase‐8‐dependent pathway (2003) (26)
Cyercenes, novel pyrones from the ascoglossan molluscCyerce cristallina. Tissue distribution, biosynthesis and possible involvement in defense and regenerative processes (1991) (26)
Endocrine disruptors in the diet of male Sparus aurata: Modulation of the endocannabinoid system at the hepatic and central level by Di-isononyl phthalate and Bisphenol A. (2018) (26)
In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. (2010) (26)
Modulation of thermo-transient receptor potential (thermo-TRP) channels by thymol-based compounds. (2012) (26)
Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis (2016) (25)
Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis (2020) (25)
Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. (2015) (25)
Protective effect of palmitoylethanolamide in a rat model of cystitis. (2015) (25)
First “hybrid” ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non‐polyunsaturated fatty acid‐derived CB2‐selective ligands (2006) (25)
Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. (1999) (25)
Prostamide F2α receptor antagonism combined with inhibition of FAAH may block the pro‐inflammatory mediators formed following selective FAAH inhibition (2014) (25)
Sesquiterpenoids from Common Ragweed (Ambrosia artemisiifolia L.), an invasive biological polluter (2012) (24)
Some like it pungent and vile. TRPA1 as a molecular target for the malodorous vinyl disulfides from asafoetida. (2013) (24)
The Synthesis of N-Vanillyl-arachidonoyl-amide (Arvanil) and its Analogs: An Improved Procedure for the Synthesis of the Key Synthon Methyl 14-Hydroxy-(all-cis)-5,8,11-tetradecatrienoate (2000) (24)
CB1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal (2017) (24)
Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy (2016) (24)
Effects of metabolites of the analgesic agent dipyrone (metamizol) on rostral ventromedial medulla cell activity in mice. (2015) (24)
Role of N-Arachidonoyl-Serotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation (2017) (24)
Analogues of perillaketone as highly potent agonists of TRPA1 channel. (2013) (24)
v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. (1998) (24)
Cannabinoids and schizophrenia: therapeutic prospects. (2014) (23)
The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. (2016) (23)
Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity (2016) (23)
Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta (2014) (23)
Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis. (2016) (23)
Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality. (2016) (23)
Mechanisms of HIV-1 Inhibition by the Lipid Mediator N-Arachidonoyldopamine1 (2005) (23)
Important role of endocannabinoid signaling in the development of functional vision and locomotion in zebrafish (2016) (22)
Fishing for Targets of Alien Metabolites: A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Agonist from a Marine Pest (2018) (22)
Exposure to Allergen Causes Changes in NTS Neural Activities after Intratracheal Capsaicin Application, in Endocannabinoid Levels and in the Glia Morphology of NTS (2015) (22)
Early Low-Fat Diet Enriched With Linolenic Acid Reduces Liver Endocannabinoid Tone and Improves Late Glycemic Control After a High-Fat Diet Challenge in Mice (2016) (22)
Endocannabinoids: An appetite for fat (2011) (22)
The anandamide membrane transporter. Structure-activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region. (2004) (22)
Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in perinatal Δ9-tetrahydrocannabinol occurs in schizophrenia: analyses in patients and in animal model of the disease. (2020) (22)
Endocannabinoid hydrolysis inhibition unmasks that unsaturated fatty acids induce a robust biosynthesis of 2‐arachidonoyl‐glycerol and its congeners in human myeloid leukocytes (2020) (22)
Characterization of endocannabinoids and related acylethanolamides in the synovial fluid of dogs with osteoarthritis: a pilot study (2017) (22)
Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent (2020) (22)
Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels (2014) (22)
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. (2016) (21)
Desulfohaplosamate, a new phosphate-containing steroid from Dasychalina sp., is a selective cannabinoid CB2 receptor ligand (2011) (21)
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. (2006) (21)
Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little effects on bronchopulmonary function and body temperature. (2012) (21)
Rimonabant in rats with a metabolic syndrome: good news after the depression (2008) (21)
Development of the first potential covalent inhibitors of anandamide cellular uptake. (2006) (20)
Role of Endocannabinoids and Cannabinoid-1 Receptors in Cerebrocortical Blood Flow Regulation (2013) (20)
Alterations of brain endocannabinoidome signaling in germ-free mice. (2020) (20)
The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain (2006) (20)
Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice (2012) (20)
Combined CoMFA and CoMSIA 3D‐QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor (2017) (20)
Possible involvement of arachidonic acid and eicosanoids in metamorphic events in Hydractinia echinata (Coelenterata; Hydrozoa). (1994) (20)
Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. (2019) (20)
Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors. (2012) (20)
Gut feelings about the endocannabinoid system (2011) (20)
Possible involvement of endocannabinoids in the increase of morphine consumption in maternally deprived rat (2013) (20)
Mooreamide A: A Cannabinomimetic Lipid from the Marine Cyanobacterium Moorea bouillonii (2014) (20)
The administration of endocannabinoid uptake inhibitors OMDM-2 or VDM-11 promotes sleep and decreases extracellular levels of dopamine in rats (2013) (20)
Biosynthesis of 2-arachidonoyl-glycerol, a novel cannabimimetic eicosanoid, in mouse neuroblastoma cells. (1997) (19)
Life-long epigenetic programming of cortical architecture by maternal ‘Western’ diet during pregnancy (2019) (19)
Endocannabinoid modulation in the olfactory epithelium. (2010) (19)
Peripheral Endocannabinoid Responses to Hedonic Eating in Binge-Eating Disorder (2017) (19)
The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders  (2020) (19)
Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands. (2015) (19)
The endogenous cannabimimetic eicosanoid, anandamide, induces arachidonate release in J774 mouse macrophages. (1997) (19)
Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: Endocannabinoidomics (2009) (18)
Effect of acyclic monoterpene alcohols and their derivatives on TRP channels. (2014) (18)
Allodynia Lowering Induced by Cannabinoids and Endocannabinoids (ALICE) (2017) (18)
Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. (2016) (18)
Manipulation of Dietary Amino Acids Prevents and Reverses Obesity in Mice Through Multiple Mechanisms That Modulate Energy Homeostasis (2020) (18)
Anandamide and decidual remodelling: COX-2 oxidative metabolism as a key regulator. (2015) (18)
The Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine. (2017) (18)
Effects of BPA on zebrafish gonads: Focus on the endocannabinoid system. (2020) (18)
Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. (2020) (18)
Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease. (2019) (18)
Endocannabinoids: An appetite for fat (2011) (18)
Overlapping Distribution of Orexin and Endocannabinoid Receptors and Their Functional Interaction in the Brain of Adult Zebrafish (2018) (18)
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. (2009) (18)
New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism. (2014) (18)
Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? (2008) (17)
Leucettamols, Bifunctionalized Marine Sphingoids, Act as Modulators of TRPA1 and TRPM8 Channels (2012) (17)
Dopamine D2 receptor signaling via the arachidonic acid cascade: modulation by cAMP-dependent protein kinase A and prostaglandin E2. (1993) (17)
Polyunsaturated-fatty-acid oxidation in Hydra: regioselectivity, substrate-dependent enantioselectivity and possible biological role. (1994) (17)
Iodinated N-Acylvanillamines: Potential “Multiple-Target” Anti-Inflammatory Agents Acting via the Inhibition of T-Cell Activation and Antagonism at Vanilloid TRPV1 Channels (2006) (17)
Palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator. (2013) (17)
Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma (2006) (17)
Effects of diisononyl phthalate (DiNP) on the endocannabinoid and reproductive systems of male gilthead sea bream (Sparus aurata) during the spawning season (2019) (16)
Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier (2019) (16)
Anandamide interferes with human endometrial stromal-derived cell differentiation: An effect dependent on inhibition of cyclooxygenase-2 expression and prostaglandin E2 release. (2016) (16)
Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: modulation at the N-portion and distal phenyl ring. (2013) (16)
Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. (2007) (16)
Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system (2019) (16)
Hepatic NAPE-PLD Is a Key Regulator of Liver Lipid Metabolism (2020) (16)
Endocannabinoid Tone Regulates Human Sebocyte Biology. (2018) (16)
Social defeat leads to changes in the endocannabinoid system: An overexpression of calreticulin and motor impairment in mice (2016) (15)
Enantiospecific synthesis of bioactive hydroxyeicosatetraenoic acids (HETEs) in Hydra magnipapillata. (1994) (15)
Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells (2016) (15)
Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation (2020) (15)
Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy (2018) (15)
Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain (2018) (15)
1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor. (2014) (15)
Role of Bisphenol A on the Endocannabinoid System at central and peripheral levels: Effects on adult female zebrafish. (2018) (14)
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels (2005) (14)
Goldfish CB1 mRNA expression is affected by fasting and anandamide administration (2009) (14)
In vitro and in vivo pharmacology of synthetic olivetol‐ or resorcinol‐derived cannabinoid receptor ligands (2006) (14)
New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. (2008) (14)
Mgll Knockout Mouse Resistance to Diet-Induced Dysmetabolism Is Associated with Altered Gut Microbiota (2020) (14)
Role of the endocannabinoid system in obesity induced by neuropeptide Y overexpression in noradrenergic neurons (2015) (14)
Endocannabinoids and multiple sclerosis: a blessing from the 'inner bliss'? (2000) (14)
New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo. (2009) (14)
Effects of Dietary Bisphenol A on the Reproductive Function of Gilthead Sea Bream (Sparus aurata) Testes (2019) (13)
Discovery of non-electrophilic capsaicinoid-type TRPA1 ligands. (2015) (13)
Cannabidiol in sport : ergogenic or else? (2020) (13)
The Endocannabinoid System – Back to the Scene of Cardiometabolic Risk Factors Control? (2014) (13)
Preparation and characterization of Δ9-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines (2013) (13)
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome (2016) (13)
TRPA1 channels as targets for resveratrol and related stilbenoids. (2016) (13)
Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): the homovanillyl moiety. (2007) (13)
Novel sterically hindered cannabinoid CB1 receptor ligands. (2008) (13)
Non-CB1, Non-CB2 Receptors for Endocannabinoids (2005) (13)
The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil (2017) (13)
Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling[S] (2019) (13)
Synthesis, binding studies and molecular modeling of novel cannabinoid receptor ligands. (2010) (13)
Prostaglandin F-1,15-lactone fatty acyl esters: a prostaglandin lactone pathway branch developed during the reproduction and early larval stages of a marine mollusc (1992) (13)
Formation of OX-1R/CB1R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. (2016) (12)
Platelet activating factor-mediated leukotriene biosynthesis in rat lungs: effect of prostaglandins E1 and F1a (1987) (12)
Rapid combinatorial access to a library of 1,5-disubstituted-3-indole-N-alkylacetamides as CB2 receptor ligands. (2009) (12)
Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration (2015) (12)
Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. (2017) (12)
N-palmitoyl-D-glucosamine, A Natural Monosaccharide-Based Glycolipid, Inhibits TLR4 and Prevents LPS-Induced Inflammation and Neuropathic Pain in Mice (2021) (12)
Human leukocytes differentially express endocannabinoid‐glycerol lipases and hydrolyze 2‐arachidonoyl‐glycerol and its metabolites from the 15‐lipoxygenase and cyclooxygenase pathways (2019) (12)
Anandamide produced by Ca2+-insensitive enzymes induces excitation in primary sensory neurons (2014) (12)
Arachidonic acid, protein kinase C activators and bud formation in Hydra vulgaris (1993) (12)
Cannabinoids: a class of unique natural products with unique pharmacology (2021) (12)
Experimental ischemia/reperfusion model impairs endocannabinoid signaling and Na+/K+ ATPase expression and activity in kidney proximal tubule cells (2018) (12)
Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo. (2016) (12)
The effect of diterpenoidic diacylglycerols on tentacle regeneration in Hydra vulgaris. (1991) (12)
Chronic blockade of CB1 receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation (2012) (12)
Design and Synthesis of New Transient Receptor Potential Vanilloid Type-1 (TRPV1) Channel Modulators: Identification, Molecular Modeling Analysis, and Pharmacological Characterization of the N-(4-Hydroxy-3-methoxybenzyl)-4-(thiophen-2-yl)butanamide, a Small Molecule Endowed with Agonist TRPV1 Activi (2016) (12)
Design, Synthesis, Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Derivatives with Anti-Osteoarthritic Activity in Vivo. (2020) (12)
Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition (2016) (12)
(Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders (2022) (11)
Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota. (2021) (11)
Targeting fatty acid amide hydrolase and transient receptor potential vanilloid‐1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N‐arachidonoyl‐serotonin (AA‐5‐HT) (2017) (11)
Fetal cannabinoid receptors and the “dis‐joint‐ed” brain (2014) (11)
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. (2014) (11)
Effects of repeated long‐term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders (2018) (11)
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action, by V. Di Marzo, D. Melck, T. Bisogno and L. De Petrocellis, Vol. 21, pp. 521–528. (1999) (11)
2-Arachidonoyl-glycerol as an "endocannabinoid": limelight for a formerly neglected metabolite. (1998) (11)
Exercise training and high-fat diet elicit endocannabinoid system modifications in the rat hypothalamus and hippocampus (2016) (11)
&Dgr;9‐tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6 (2018) (11)
Tetrahydro-β-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels. (2013) (11)
Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (10)
Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine (2019) (10)
Rational drug design paradigms: the odyssey for designing better drugs. (2014) (10)
Treatment With 2-Pentadecyl-2-Oxazoline Restores Mild Traumatic Brain Injury-Induced Sensorial and Neuropsychiatric Dysfunctions (2020) (10)
Occurrence and biosynthesis of 11 (R)-hydroxy-eicosatetraenoic acid (11-R-HETE) in the Caribbean soft coralPlexaurella dichotoma (1996) (10)
1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands. (2011) (10)
In Silico Identification and Experimental Validation of (−)-Muqubilin A, a Marine Norterpene Peroxide, as PPARα/γ-RXRα Agonist and RARα Positive Allosteric Modulator (2019) (10)
Cell signalling: Why fasting worms age slowly (2011) (10)
Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB(1) receptors. (2003) (10)
Expression and Functions of the CB2 Receptor in Human Leukocytes (2022) (10)
Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract (2020) (10)
Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile. (2009) (10)
Arylboronic acids as dual-action FAAH and TRPV1 ligands. (2016) (10)
Anandamide-loaded nanoparticles: Preparation and characterization (2011) (9)
Orexin-A and endocannabinoids are involved in obesity-associated alteration of hippocampal neurogenesis, plasticity, and episodic memory in mice (2021) (9)
Lipids in neural function: modulation of behavior by oral administration of endocannabinoids found in foods. (2001) (9)
Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor. (2011) (9)
Placebo Effects in a Multiple Sclerosis Spasticity Enriched Clinical Trial with the Oromucosal Cannabinoid Spray (THC/CBD): Dimension and Possible Causes (2015) (9)
2-Arachidonoyl-glycerol as an "endocannabinoid": limelight for a formerly neglected metabolite. (1998) (9)
Biology of endocannabinoids (2002) (9)
Genetic Manipulation of sn-1-Diacylglycerol Lipase and CB1 Cannabinoid Receptor Gain-of-Function Uncover Neuronal 2-Linoleoyl Glycerol Signaling in Drosophila melanogaster. (2021) (9)
New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. (2006) (9)
The endocannabinoid system for the development of new drugs for spasticity (2007) (9)
Role of the endocannabinoid system in the control of mouse myometrium contractility during the menstrual cycle (2017) (9)
Arachidonic acid as an endogenous signal for the glutathione-induced feeding response in Hydra (1997) (9)
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists. (2018) (9)
Enantioselective synthesis of 3(S)-hydroxy polygodial derivatives and evaluation of their vanilloid activity (2010) (9)
β-Casomorphins: substitution of phenylalanine with β-homo phenylalanine increases the μ-type opioid receptor affinity (2000) (9)
Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): The side chain benzylic methylene. (2010) (9)
Biosynthesis of the Novel Endogenous 15-Lipoxygenase Metabolites N-13-Hydroxy-octodecadienoyl-ethanolamine and 13-Hydroxy-octodecadienoyl-glycerol by Human Neutrophils and Eosinophils (2021) (9)
Cannabinoids in the Treatment of Neurological Disorders (2015) (8)
Brain and peripheral anandamide amidohydrolase and its inhibition by synthetic arachidonate analogues. (1997) (8)
Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation (2021) (8)
Endocannabinoids in Energy Homeostasis and Metabolic Disorders (2008) (8)
Hedonic eating in Prader–Willi syndrome is associated with blunted PYY secretion (2017) (8)
Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague–Dawley rats (2019) (8)
Coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma ß-cells (2007) (8)
Endocannabinoid-dependent disinhibition of orexinergic neurons: Electrophysiological evidence in leptin-knockout obese mice (2017) (8)
Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ9-Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues. (2017) (8)
Structure-Based Virtual Screening: Identification of Novel CB2 Receptor Ligands (2007) (8)
Aquatic invertebrates open up new perspectives in eicosanoid research: biosynthesis and bioactivity. (1994) (8)
Anandamide serves two masters in the brain. (2010) (8)
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 ( TRPA 1 ) and melastatin type-8 ( TRPM-8 ) (2008) (7)
Novel diterpenoid diacylglycerols from marine molluscs: potent morphogens and protein kinase C activators (1996) (7)
Orexin-A/Hypocretin-1 Controls the VTA-NAc Mesolimbic Pathway via Endocannabinoid-Mediated Disinhibition of Dopaminergic Neurons in Obese Mice (2021) (7)
Design, Synthesis and In Vitro Experimental Validation of Novel TRPV4 Antagonists Inspired by Labdane Diterpenes (2020) (7)
Endocannabinoids in the new millennium. (2002) (7)
Neuropeptides and leukotriene release: Effect of peptide histidine isoleucine and secretin in platelet activating factor-stimulated rat lung (1987) (7)
International Association for Cannabinoid Medicines (2013) (7)
Hydra Tentacle Regeneration: A Model for the Study of the Involvement of Protein Kinase C and Phospholipase A2 in Cell Differentiation (1993) (7)
2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors (2021) (7)
Adverse effects of Δ9-tetrahydrocannabinol on neuronal bioenergetics during postnatal development (2020) (7)
The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders . (2020) (7)
Enantioselective synthesis and vanilloid activity evaluation of 1-beta-(p-methoxycinnamoyl)polygodial, an antinociceptive compound from Drymis winteri barks. (2007) (7)
Synthesis and Biological Evaluation of Phorbol‐Resiniferatoxin (RTX) Hybrids (2004) (7)
Manipulation of the endocannabinoid system by a general anaesthetic. (2003) (7)
Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1. (2021) (7)
Metabolically labile cannabinoid esters: a 'soft drug' approach for the development of cannabinoid-based therapeutic drugs. (2007) (7)
Endocannabinoids, food intake and body weight (2004) (7)
Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats (2020) (7)
Iron overload causes osteoporosis in Thalassemia Major patients through interaction with TRPV 1 channels (2014) (7)
Inhibitors of endocannabinoid breakdown for pain: not so FA(AH)cile, after all. (2012) (6)
Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. (2004) (6)
Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet (2016) (6)
Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands. (2010) (6)
Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models (2021) (6)
Synthesis of a potential photoactivatable anandamide analog. (2006) (6)
Innenrücktitelbild: Development of an Activity-Based Probe and In Silico Design Reveal Highly Selective Inhibitors for Diacylglycerol Lipase-α in Brain (Angew. Chem. 46/2013) (2013) (6)
Phospholipase A2 and protein kinase C enzymatic activities and their interactions in Hydra vulgaris (1995) (6)
Synthesis and molecular targets of N-13-hydroxy-octadienoyl-ethanolamine, a novel endogenous bioactive 15-lipoxygenase-derived metabolite of N-linoleoyl-ethanolamine found in the skin and saliva. (2021) (6)
Inhibitory effect of positively charged triazine antagonists of prokineticin receptors on the transient receptor vanilloid type-1 (TRPV1) channel. (2015) (6)
Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs (2001) (6)
The possible involvement of protein kinase C and phospholipase A2 inHydra tentacle regeneration (2005) (6)
Arachidonic acid and eicosanoids in Hydra: possible endogenous signals involved in chemoreception and modulation of the feeding behaviour. (1997) (6)
Synthesis, conformational analysis and CB1 binding affinity of hairpin‐like anandamide pseudopeptide mimetics (2006) (6)
Biosynthesis of hydroxyeicosatetraenoic acids (HETEs) in marine and freshwater hydroids (1993) (5)
Corrigendum: New approaches and challenges to targeting the endocannabinoid system (2018) (5)
Techniques for the Cellular and Subcellular Localization of Endocannabinoid Receptors and Enzymes in the Mammalian Brain. (2017) (5)
Protective effects of N-oleoylglycine in a mouse model of mild traumatic brain injury. (2020) (5)
Enantioselective synthesis of 1-(R)-hydroxypolygodial and its 9α epimer, 1-(R)-hydroxyisotadeonal (2007) (5)
Alterations of the endocannabinoid system and circulating and peripheral tissue levels of endocannabinoids in sarcopenic rats (2021) (5)
The Endocannabinoid System in Leptin-Driven Changes of Orexinergic Signaling Under Physiological and Pathological Conditions (2017) (5)
Role of 2-Arachidonoyl-Glycerol and CB1 Receptors in Orexin-A-Mediated Prevention of Oxygen–Glucose Deprivation-Induced Neuronal Injury (2020) (5)
N‐Acylethanolamine acid amidase (NAAA) is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth (2021) (5)
Manipulation of the endocannabinoid system by a general anaesthetic (2003) (5)
“De-liver-ance” From CB1: A Way to Counteract Insulin Resistance? (2012) (5)
Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis (2019) (5)
Why Can't We Be Friends? The Banning of Teacher-Student Communication Via Social Media and the Freedom of Speech (2012) (5)
Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome (2021) (5)
The Synthesis of N‐Vanillyl‐arachidonoyl‐amide (Arvanil) and Its Analogues: An Improved Procedure for the Synthesis of the Key Synthon Methyl 14‐Hydroxy‐(all‐cis)‐5,8,11‐tetradecatrienoate. (2001) (4)
Erratum to “The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats” [Life Sciences 70(12) (2002) 1407-1414] (2002) (4)
Endocannabinoid system and its role in energy regulation (2006) (4)
β-Endorphin in Neoroblastoma x Glioma hybrid cells (1985) (4)
Cannabidiol improves vocal learning-dependent recovery from, and reduces magnitude of deficits following, damage to a cortical-like brain region in a songbird pre-clinical animal model (2019) (4)
Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint (2022) (4)
Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia (2022) (4)
Spontaneous and Naloxone-Precipitated Withdrawal Behaviors From Chronic Opiates are Accompanied by Changes in N-Oleoylglycine and N-Oleoylalanine Levels in the Brain and Ameliorated by Treatment With These Mediators (2021) (4)
PL03 Biochemistry and pharmacology of fatty acid amides – effects on inflammation, pain and pruritus and new perspectives in veterinary medicine (2006) (4)
Impact of omega‐6 polyunsaturated fatty acid supplementation and γ‐aminobutyric acid on astrogliogenesis through the endocannabinoid system (2013) (4)
"De-liver-ance" from CB(1): a way to counteract insulin resistance? (2012) (4)
Correction to Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. (2020) (4)
Fifty years of ‘cannabinoid research’ and the need for a new nomenclature (2014) (4)
Potential use of cannabimimetics in the treatment of cancer (2005) (4)
Neuropeptides and leukotriene biosynthesis: The effect of calcitonin, peptide histidine valine-42, helodermin, neuropeptide Y and galanin (1988) (4)
N-Oleoylglycine and N-Oleoylalanine Do Not Modify Tolerance to Nociception, Hyperthermia, and Suppression of Activity Produced by Morphine (2021) (3)
FAAH-Catalyzed C-C Bond Cleavage of a New Multitarget Analgesic Drug. (2018) (3)
Alteration of the endocannabinoid system in mouse brain during prion disease (2011) (3)
Enzymological and molecular biological studies on anandamide amidohydrolase. (1999) (3)
The Endocannabinoid System: Can It Contribute to Cannabis Therapeutics? (2008) (3)
Effect of narrowband ultraviolet B treatment on endocannabinoid plasma levels in patients with psoriasis (2014) (3)
PAF-mediated leukotriene biosynthesis in lungs : Control by the neuropeptidergic system (1987) (3)
Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp (Eur. J. Org. Chem. 11/2010) (2010) (3)
Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol andN-acyl-ethanolamine families. (2022) (3)
Native opioid-like peptides in Squilla mantis ganglia (1985) (3)
714 Randomized Placebo-Controlled Multicenter Study on the Effect of Palmitoyl-Ethanolamide and Polydatin on Immune Activation in Patients With Irritable Bowel Syndrome (2014) (3)
Cannabinoids and Chronic Liver Diseases (2022) (3)
A novel prostaglandin metabolic pathway from a marine mollusc: prostaglandin-1,15-lactones. (1991) (3)
PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines. (2013) (3)
Signalling at vanilloid TRPV1 channels (2004) (3)
Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction. (2011) (3)
Oral Capsaicinoid Administration Alters the Plasma Endocannabinoidome and Fecal Microbiota of Reproductive-Aged Women Living with Overweight and Obesity (2021) (3)
Regulation of Endocannabinoid Levels under Physiological and Pathological Conditions. A Mini‐review (2000) (3)
Calcitonin gene-related peptide antagonises leukotriene D4-mediated contraction of the isolated guinea pig ileum (1986) (3)
RIA/chromatographic evidence for novel opioid peptide(s) in Squilla mantis ganglia (1986) (3)
Targeted Lipidomics Investigation of N ‐acylethanolamines in a Transgenic Mouse Model of AD: A Longitudinal Study (2019) (3)
Dual role of neuropeptidergic system in pathology of asthma (1987) (3)
Erratum to: Cannabinoids in the Treatment of Neurological Disorders (2015) (2)
Increased skin levels of the Aliamide Palmitoylethanolamide and other endogenous fatty acid amides in dogs with atopic dermatitis (2008) (2)
New Potential Therapies from Vanilloid Transient Receptor Cation (TRPV) Channels. (2008) (2)
β‐Casomorphins: Substitution of Phenylalanine with β‐homo Phenylalanine Increases the μ‐Type Opioid Receptor Affinity. (2000) (2)
Neuromodulatory actions neuromodulatory actions of endocannabinoids in pain and sedation. (2003) (2)
5 Anandamide and Other Acylethanolamides (2009) (2)
The role of consciousness in biological cybernetics: emergent adaptive and maladaptive behaviours in artificial agents governed by the projective consciousness model (2020) (2)
Mechanisms underlying in vivo neuroprotection by the endocannabinoid anandamide and the cannabinoid/vanilloid receptor agonist, arvanil (2003) (2)
A Glucuronic Acid-Palmitoylethanolamide Conjugate (GLUPEA) Is an Innovative Drug Delivery System and a Potential Bioregulator (2021) (2)
N-Acyldopamines and N-Acylserotonins: From Synthetic Pharmacological Tools to Endogenous Multitarget Mediators (2015) (2)
Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? (2008) (2)
ORIGINAL ARTICLE The cannabinoid D 9 -tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity (2013) (2)
Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis (2021) (2)
The ever-expanding world of the endocannabinoids: A concise introduction (2015) (2)
Human and Mouse Eosinophils Differ in Their Ability to Biosynthesize Eicosanoids, Docosanoids, the Endocannabinoid 2-Arachidonoyl-glycerol and Its Congeners (2022) (2)
Intuitive eating is associated with elevated levels of circulating omega-3-polyunsaturated fatty acid-derived endocannabinoidome mediators (2020) (2)
Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure. (2021) (2)
Hemp seed significantly modulates the endocannabinoidome and produces beneficial metabolic effects with improved intestinal barrier function and decreased inflammation in mice under a high-fat, high-sucrose diet as compared with linseed (2022) (2)
Alterations in the Endocannabinoid System as a Link Between Unbalanced Energy Homeostasis, Neuroinflammation, and Neurological and Neuropsychiatric Disorders (2013) (2)
The endocannabinoid system in metabolic control: a preface. (2009) (2)
Cannabimimetic eicosanoids in cancer and inflammation: an update. (2002) (2)
The Palmitoylethanolamide and Oleamide Enigmas: Are These Two Fatty Acid Amides Cannabimimetic? (1999) (2)
Hydra vulgaris ω10-lipoxygenase is used in vivo to synthesize new α-linolenic acid metabolites (2005) (2)
THE ENDOGENOUS CANNABINOID SIGNALING SYSTEM: CHEMISTRY AND PHYSIOLOGY (1997) (2)
Endocannabinoid-Based Molecules as Potential Therapeutic Drugs (2005) (2)
Maternal omega-3 intake differentially affects the endocannabinoid system in the progeny`s neocortex and hippocampus: impact on synaptic markers: n-3 maternal diet sway progeny`s synaptic markers. (2021) (2)
Novel mechanisms in obesity, type 2 diabetes and accompanying inflammation: focus on lipid signaling (2010) (1)
Inside Back Cover: Development of an Activity-Based Probe and In Silico Design Reveal Highly Selective Inhibitors for Diacylglycerol Lipase-α in Brain (Angew. Chem. Int. Ed. 46/2013) (2013) (1)
Corrigendum to "Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system" [Biochem. Pharmacol. 161 (2019) 37-51]. (2019) (1)
Neuroendocrine Responses to Hedonic Eating in Obese Patients with and Without Binge Eating (2015) (1)
REVIEW Role and regulation of acylethanolamides in energy balance: focus on adipocytes and b -cells (2007) (1)
Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction (2011) (1)
CB1, but not CB2, mediates stimulation of bone formation induced by traumatic brain injury. (2006) (1)
Anandamides and Diet: A New Pot of Nutritional Research is Simmering (2004) (1)
Su1124 SMALL INTESTINE EPITHELIAL ORGANOIDS AS A MODEL TO INVESTIGATE THE ROLE OF THE ENDOCANNABINOIDOME ON INTESTINAL PARACELLULAR PERMEABILITY DURING INFLAMMATION (2020) (1)
The endocannabinoid system in metabolic control: a preface. (2009) (1)
Positive association between plasmatic levels of orexin A and the endocannabinoid-derived 2-arachidonoyl lysophosphatidic acid in Alzheimer’s disease (2022) (1)
739 CIRCULATING AND HEPATIC ENDOCANNABINOIDS AND ENDOCANNABINOID-RELATED MOLECULES IN PATIENTS WITH LIVER CIRRHOSIS (2009) (1)
Abdominal Obesity and the Endocannabinoid System: From Basic Aspects to Clinical Management of Related Cardiometabolic Risk (2008) (1)
Preparation and characterization of D 9-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines (2016) (1)
G02 Identification of functional TRPV1 vanilloid receptor in MCF-7 cells (2006) (1)
Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity. (2020) (1)
α2-Adrenoceptor agonist induces peripheral antinociception via the endocannabinoid system (2020) (1)
Beta-casomorphins: substitution of phenylalanine with beta-homo phenylalanine increases the mu-type opioid receptor affinity. (2000) (1)
Established and Emerging Concepts of Cannabinoid Action on Food Intake and their Potential Application to the Treatment of Anorexia and Cachexia (2014) (1)
STUDIES ON THE IN VITRO PHARMACOLOGY AND METABOLISM OF PROSTAGLANDIN–ETHANOLAMIDES (PROSTAMIDES) IN THE FELINE IRIS (2004) (1)
Corrigendum to Halogenation of a capsaicin analogue leads to novel vanilloid TRPVI receptor antagonists (2003) (1)
Phytocannabinoids: a growing family of plant natural products with increasing pharmacological and clinical importance (2016) (1)
Cannabinoids: Di Marzo/Cannabinoids (2014) (1)
P.1.g.064 Possible dysregulation of the endocannabinoid system in a cohort of patients with Dravet syndrome (2016) (1)
Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men (2013) (1)
Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model (2021) (1)
Endocannabinoid Overactivity and Abdominal Obesity (2008) (1)
Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors (2013) (1)
ω10-Lipoxygenase products of α-linolenic acid are esterified to phospholipids inHydra vulgaris (1996) (1)
Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer. (2023) (1)
TRPV1 in Neuropathic Pain and Neurological and Neuropsychiatric Disorders (2010) (1)
Naphthalene and 2,3-dihydrobenzo[b][1,4]dioxine derivatives with extended side chains as new scaffolds of CB2-selective ligands (2014) (1)
Synthesis and binding study of certain 6-arylalkanamides as molecular probes for cannabinoid receptor subtypes (2013) (1)
Correction to: 2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors (2021) (1)
Function of endocannabinoids and related compounds in sleep (2008) (1)
Cannabinoid Properties of Methylfluorophosphonate Analogs 1 (2000) (1)
Studies on the Interactions of Prostamides With Fatty Acid Amide Hydrolase, the Anandamide Transporter, and VR1 Receptors (2002) (1)
Different targets of anti-glucocorticoid treatment have been proposed, acting at supra-hypothalamic, HPA axis, glucocorticoid receptor and post-receptor levels. (2013) (1)
Study of the expression profile and pharmacological role of the CB 1 receptor in Duchenne Muscular Dystrophy ( DMD ) muscles : a new opportunity to reinforce muscle repair and locomotor activity (2015) (0)
30 P The endocannabinoid system and colorectal carcinoma a possible role in the inhibition of cancer growth (2002) (0)
CB1 cannabinoid receptors mediate cognitive deficits and structural plasticity changes associated with nicotine withdrawal (2017) (0)
Involvement of the endocannabinoid system in a neurodevelopmental model of schizophrenia (2015) (0)
DESIGN, SYNTHESIS, AND EVALUATION OF (ISO)NIPECOTAMIDE ANDPIPERAZINYLUREA DERIVATIVES AS TRPV1 MODULATORS (2013) (0)
Dual control by cannabinoid CB1 and CB2 receptors of S100B protein expression and glial cell proliferation following administration of beta amyloid in vitro and in vivo. (2006) (0)
Have you seen ? Fetal cannabinoid receptors and the “ disjointed ” brain (2014) (0)
NAPE-PLD, 12-LOX and TRPV1 immunoexpression in the hippocampus and cerebellum of the mouse brain (2007) (0)
Phytocannabinoids in cancer treatment (2011) (0)
Participants with Normal Weight or with Obesity Show Different Relationships of 6-n-Propylthiouracil (PROP) Taster Status with BMI and Plasma Endocannabinoids (2017) (0)
The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil (2017) (0)
Short and efficient synthesis of alkylresorcinols: a route for the preparation of cannabinoids (2022) (0)
250 ANANDAMIDE CAUSES ANALGESIA IN NEUROPATHIC RATS BY ACTIVATING SPINAL TRPV1 RECEPTORS (2009) (0)
Synthesis and antitumor evaluation of 1,8-naphthyridine-2-(1H)-on-3carboxamide derivatives as CB2 selective agonists (2008) (0)
37 ANTINOCICEPTIVE TR(i)PS FROM SUPRASPINAL ENDOVANILLOID SIGNALLING TO PLANT CANNABINOIDS (2009) (0)
Differential effects of EPA and DHA on plasma and adipose tissue lipid mediators: the ComparED study (2020) (0)
Author Correction: CB1 receptor activation induces intracellular Ca2+ mobilization and 2-arachidonoylglycerol release in rodent spinal cord astrocytes (2018) (0)
Comprar Abdominal Obesity and the Endocannabinoid System: From Basic Aspects to Clinical Management of Related Cardiometabolic Risk | Jean-Pierre Despres | 9781420060843 | Informa Healthcare (2008) (0)
Regulation on spinal nociceptive TRPV1/CB1 processing as therapeutic opportunities in a rat model of neuropathic pain (2011) (0)
Enantioselective Synthesis and Vanilloid Activity Evaluation of 3-B-Hydroxypolygodial and its Analogues (2009) (0)
Cannabichromene (CBC), cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA) for the treatment of neurodegenerative diseases (2012) (0)
Abdominal obesity and the endocannabinoid system (2014) (0)
Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity (2016) (0)
Phytocannabinoids: a growing family of plant natural products with increasing pharmacological and clinical importance (2016) (0)
Exogenous and endogenous : Cannabimimetic metabolites (1998) (0)
Luciano De Petrocellis-CNS&ND-MS (2016) (0)
Olivetol- and Resorcinol-Anandamide “hybrids”: design, synthesis, binding and molecular modeling of potent cannabinoid receptor ligands (2007) (0)
S.11.03 Cannabinoid receptor antagonists and inhibitors of endocannabinoid metabolism as potential therapeutic drugs (2004) (0)
196 The endocannabinoid tone regulates human sebocyte biology (2016) (0)
A1 ADENOSINE RECEPTOR REGULATES ATP-MEDIATED MICROGLIAL ACTIVATION IN VIVO AND IN VITRO: ROLE IN THE SPINAL NEURONAL PLASTICITY IN NEUROPATHIC MICE (2013) (0)
Synthesis, release and action of leukotrienes in the isolated rat heart (1988) (0)
Distribution and Activity of Fatty Acid Amide Hydralase (FAAH) in the Gastrointestinal Neurons of Mouse (2005) (0)
Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity (2019) (0)
Skin mast cells and endogenous fatty acid amides in canine atopic dermatitis: a pilot study. (2008) (0)
184 Regulation of the Enteric Neuromotor and Sensory Functions in the Mouse With N-Arachidonoyl-Serotonin (AA-5-HT), a Dual Fatty Acid Amide Hydrolase (FAAH) Inhibitor and TRPV1 Antagonist (2016) (0)
Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp. (2010) (0)
Early modulation of the endocannabinoid tone prevents the onset of a schizophrenia-likephenotype (2017) (0)
EPA-0534 - Endocannabinoid and Gastroenteric Hormone Responses to Hedonic Eating in Humans: Implications for Eating Disorders (2014) (0)
Mo-S4:3 CB1 blockade, a new therapeutic target for the treatment of cardiometabolic disorders: Mechanism(s) of action (2006) (0)
2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons (2015) (0)
The Endocannabinoid System and its Modulation by Phytocannabinoids (2015) (0)
The endocannabinoidome in human placenta: Possible contribution to the pathogenesis of preeclampsia. (2023) (0)
CB1 receptor activation induces intracellular Ca2+ mobilization and 2-arachidonoylglycerol release in rodent spinal cord astrocytes (2018) (0)
Differences In Serum Levels Of Lysophosphatidic Acid And Orexin/Hypocretin In Normal Weight And Obese Patients,Along The Continuum From Health People To Alzheimer’s Disease (2018) (0)
(Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders (2022) (0)
Facile and Sustainable Synthesis of Commendamide and its Analogues (2022) (0)
Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract (2020) (0)
Targeted lipidomics: endocannabinoids and other endolipid modulators (2005) (0)
Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer (2012) (0)
Plasma OEA level is correlated with muscle mass and mobility in old rats (2020) (0)
Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine (2019) (0)
2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors (2021) (0)
EPA-1474 – Psychosocial Stress and Psychiatric Phenotypes: Endocannabinoids and Cannabinoid Receptor (CBR) Expression in Cortico-Striatal Connectivity (2014) (0)
The EC System and Central Control of Energy Balance—The Hypothalamus (2008) (0)
Anandamide produced by Ca2+-insensitive enzymes induces excitation in primary sensory neurons (2013) (0)
Potential drug metabolites as endocannabinoids and endovanilloids (2007) (0)
Functional Plasticity of Lipid Mediators: The Example of Endocannabinoids (2005) (0)
Effects of diisononyl phthalate (DiNP) on the endocannabinoid and reproductive systems of male gilthead sea bream (Sparus aurata) during the spawning season (2019) (0)
Design, synthesis, and biological evaluation of new heterocyclic azotate derivatives as CB2 selective agonists (2007) (0)
Activation of cannabinoid type 1 receptor (CB1) modulates oligodendroglial process branching complexity in rat hippocampal cultures stimulated by olfactory ensheathing glia-conditioned medium (2023) (0)
Human eosinophils and neutrophils biosynthesize novel 15-lipoxygenase metabolites from 1-linoleoyl-glycerol and N-linoleoyl-ethanolamine (2020) (0)
endoCANNABINOIDS (2013) (0)
First Evidence of the Protective Effects of 2-Pentadecyl-2-Oxazoline (PEA-OXA) in In Vitro Models of Acute Lung Injury (2022) (0)
Neuropeptides and leukotriene biosynthesis (1988) (0)
Exercise training and high-fat diet elicit endocannabinoid system modifications in the rat hypothalamus and hippocampus (2016) (0)
Synthesis of potential theanine metabolites, related structures and their affinity for CB receptors (2007) (0)
This first 2014 issue of Recent Patents in CNS Drug Discovery covers a range of rather diverse, but not necessarily unrelated topics. Introduction. (2014) (0)
Questions & Answers (2011) (0)
344 SPINAL VANILLOID TRPV1 RECEPTOR AS A TARGET FOR ENDOGENOUS ANANDAMIDE IN NEUROPATHIC PAIN (2010) (0)
Pathogenesis of the metabolic syndrome and the influence of cannabinoids (2008) (0)
Cannabinoids in the Treatment of Neurological Disorders (2015) (0)
The effect of hyperinsulinaemic-euglycaemic clamp on circulating endocannabinoids in insulin sensitive vs. insulin-resistant obese post-menopausal women (2011) (0)
The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity (2022) (0)
Use of cannabinoids comprising cannabichromene, cannabidivarin and cannabidivarin acid, for preventing or treating neurodegenerative diseases or disorders e.g. Alzheimer's disease, Parkinson's disease, cardiac ischemia and stroke (2013) (0)
Rational design, synthesis, biological evaluation and labelling of selective cannabinoid CB2 receptor agonists as anticancer agents (2011) (0)
Krill Oil supplementation modifies endocannabinoid congeners profile in cachectic advanced cancer patients (2014) (0)
Phytocannabinoids in ther treatment of cancer (2010) (0)
Endocannabinoid and Gastroenteric Hormone Responses to Hedonic Eating in Healthy Humans: Implications for Eating Disorders (2014) (0)
Decrease of anandamide ratio between visceral and subcutaneous adipose tissues by dietary EPA and DHA phosphatidylcholine improves metabolic syndrome in obese zucker rats (2012) (0)
Track 2: From genes and environment to pathophysiology (2014) (0)
New biphenylic derivatives as CB2 receptor selective ligands (2013) (0)
"Soft Drugs" Based on Cannabinoid Receptor Ligands as Potential Local Analgesic and Antiglaucoma Agents (2007) (0)
UMBELLULONE, THE OFFENSIVE PRINCIPLE OF THE HEADACHE TREE (UMBELLULARIA CALIFORNICA), STIMULATES THE TRIGEMINOVASCULAR SYSTEM VIA TRPA1 ACTIVATION (2011) (0)
P.3.c.010 Early pharmacological modulation of the endogenous cannabinoid signaling counteracts the phenotype in a rodent developmental disruption model of schizophrenia at adulthood (2016) (0)
Article: EPA-0534 Topic: E06-e-Poster Oral Session 06: Child Psychiatry and Personality Disorders ENDOCANNABINOID AND GASTROENTERIC HORMONE RESPONSES TO HEDONIC EATING IN HUMANS: IMPLICATIONS FOR EATING DISORDERS (2014) (0)
3-Hydroxy-oxylipins and derivatives, novel fungal lipid mediators produced by host–pathogen interaction, activate capsaicin receptor (TRPV1): A mechanism for pain in vulvovaginal candidiasis (2007) (0)
' s report Title : Synergistic action of N-palmitoylethanolamine and the FAAH inhibitor URB 597 on melanoma growth Version : 1 Date : 11 November 2011 (0)
CB1 and CB2-independent neuroprotective effects of oxyhomologs of palmitoyl ethanolamine on an in vitro model of oxidative stress (2005) (0)
A Gradient of 2-Arachidonoylglycerol Regulates Mouse Epididymal Sperm Cell Start-Up Short title: 2-AG regulates sperm motility (2009) (0)
Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy (2018) (0)
Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders (2015) (0)
Peripubertal cannabidiol treatment prevents molecular and behavioral changes in neurodevelopmental model of schizophrenia (2018) (0)
Retinal projections to the lateral hypothalamus are involved in the light-mediated endocannabinoid synthesis: Orexin and 2-acylglicerol interaction in the light-entrainable rhythms. (2011) (0)
Rapid Participation of Prostaglandin E, in Dopamine D2 Receptor-Dependent Potentiation of Arachidonic Acid Release (2006) (0)
Abstracts of the 6th Meeting of the Neapolitan Brain Group (2018) (0)
P.1.c.007 Prenatal influences facilitate the precipitation of a schizophrenia-like phenotype: assessing the role of the endocannabinoid system (2015) (0)
Cover Picture: Synthesis and Biological Evaluation of Phorbol-Resiniferatoxin (RTX) Hybrids (Eur. J. Org. Chem. 16/2004) (2004) (0)
Abdominal Obesity As a Therapeutic Target to Manage the Atherogenic Dyslipidemia and Related Metabolic Abnormalities (2008) (0)
202 TRPV1 AND MU OPIOID RECEPTOR COMBINED ACTIVATION INDUCES ANALGESIA VIA BRAINSTEM DESCENDING ANTINOCICEPTIVE PATHWAYS (2009) (0)
Abdominal Obesity, Metabolic Syndrome and Risk of Cardiovascular Disease (2008) (0)
Orexin induces the production of an endocannabinoid-derived lysophosphatidic acid eliciting hypothalamic synaptic loss in obesity. (2023) (0)
ResearchAnandamide and Palmitoylethanolamide involvement in human stroke (2010) (0)
Enantioselective Synthesis and Vanilloid Activity Evaluation of 1-β-(p-Methoxycinnamoyl)polygodial (I), an Antinociceptive Compound from Drymis winteri Barks. (2008) (0)
A Designer Diet Induces Thermogenic Adipocytes via Raptor and Prolongs Healthy Lifespan (2019) (0)
Endocannabinoid signalling: a common target for high fat diets and substances of abuse? (2005) (0)
Phytocannabinoidome and the Endocannabinoidome: How Close Are They? (2018) (0)
Opioid-cannabinoid interactions: A general introduction to the endocannabinoid system and its interactions with opioid receptor signalling (2011) (0)
Endocannabinoid system and schizophrenia: behavioral andmolecular changes in neurodevelopmental animal model (2016) (0)
Endocannabinoids and endocannabinoid-related molecules in patients with liver cirrhosis (2009) (0)
Research Article Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain (2004) (0)
Nitric Oxide Endothelial Cells and Its Regulation by Anandamide Uptake by Human TRANSDUCTION: MECHANISMS OF SIGNAL (2019) (0)
Validation of a fast and sensitive UPLC-MS/MS quantitative method for N-acyl taurine analysis in biological samples (2023) (0)
Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet (2016) (0)
Design, synthesis, and biological evaluation of 1,8-naphthyridin-2(1H)-on-3-carboxamide, quinolin-2(1H)-on-3-carboxamide and 2-oxo-1,2-dihydropyridine-3-carboxamide derivatives as CB2 selective ligands (2008) (0)
Studies on Endocannabinoid Levels in Normal and Glaucomatous Eyes (2005) (0)
Impact of dietary fat on the endocannabinoid system (2011) (0)
Critical role of the endocannabinoid system in bone homeostasis (2007) (0)
Erratum to: Cannabinoids in the Treatment of Neurological Disorders (2015) (0)
Cannabinoid–vanilloid receptor interactions in pain signaling (2003) (0)
Abstract: 69 IS HEPATIC STEATOTIS THE CULPRIT OF DYSLIPIDEMIA IN SUBJECTS WITH ABDOMINAL OBESITY? (2009) (0)
Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague–Dawley rats (2019) (0)
P.1.d.012 Role of the endocannabinoid system and vanilloid TRPV1 channels in the phenotype of dopamine D3 receptor knock-out mice (2009) (0)
New Substituted 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as High Affinity hCB1 Ligands (2009) (0)
Kahweol, a natural diterpene from coffee, induces peripheral antinociception by endocannabinoid system activation (2021) (0)
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice (2023) (0)
Erratum to: Responses of peripheral endocannabinoids and endocannabinoid‑related compounds to hedonic eating in obesity (2016) (0)
S9 CANNABINOID RECEPTORS AND THEIR ROLE IN NEUROPROTECTION (2006) (0)
Fatty acid derivatives of phenethylamine and glycerol as endocannabinoids and endovanilloids (2012) (0)
Cell signalling: why fasting worms age slowly. (2011) (0)
Different targets of anti-glucocorticoid treatment have been proposed, acting at supra-hypothalamic, HPA axis, glucocorticoid receptor and post-receptor levels. (2013) (0)
Gene deletion studies reveal a critical role for prostamide/prostaglandin F2α synthase in prostamide F2α formation (2020) (0)
Compositions and methods for modulating specific for N-acylethanolamines amidases to be used in the therapy of inflammatory diseases (2012) (0)
Title Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain Permalink (2016) (0)
Meet Our Editor (2015) (0)
Stimulation of CB2 directly stimulates cell survival pathways. (2013) (0)
P4.033 The amnesic effects induced by β-amyloidfragment 1–42 involve cannabinoid neurotransmission in the brain (2004) (0)
Regulation of intracellular calcium in insulinoma cells by bombesin and cannabinoids: same coupling for different informations? (2007) (0)
A Lipidomics- and Transcriptomics-Based Analysis of the Intestine of Genetically Obese (ob/ob) and Diabetic (db/db) Mice: Links with Inflammation and Gut Microbiota (2023) (0)
Cannabimimetic eicosanoids: An overview of their metabolic pathways and potential role in cancer and inflammation (1999) (0)
Endocannabinoids in the new millennium. (2002) (0)
Synthesis and biological evaluation of pyridine derivatives as cannabinoid receptor ligands (2009) (0)
Tu1205 OBESITY-RELATED ENDOGENOUS MICROENVIRONMENT IMPACTS INSULIN SIGNALING AND INTESTINAL FUNCTIONS OF INTESTINAL ORGANOIDS (2020) (0)
P.705 Neonatal CB1 receptor blockade differentially affects behavioural responses in normal and prenatally MAM exposed rats (2019) (0)
Special Issue: The endocannabinoid system in metabolic control. (2009) (0)
The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology (2023) (0)
Human and murine eosinophils differ in their ability to synthesize key bioactive lipids involved in asthma (2020) (0)
The cannabinoid receptor type 2 is down-regulated in downstream portions of human carotid plaques (2012) (0)
The effects of CB1-receptor blockade on mean arterial pressure (A) and cerebrocortical blood flow (B). (2013) (0)
High-Voltage-Activated Calcium Currents in Cannabinoids Modulate the P-Type (2015) (0)
Synthesis and biological evaluation of 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists (2007) (0)
Use of cannabinoids comprising cannabichromene, cannabidivarin and cannabidivarin acid, for preventing or treating neurodegenerative diseases or disorders e.g. Alzheimer's disease, Parkinson's disease, cardiac ischemia and stroke (2013) (0)
Author Correction: CB1 receptor activation induces intracellular Ca2+ mobilization and 2-arachidonoylglycerol release in rodent spinal cord astrocytes (2018) (0)
TRPV1 modulators: Synthesis and in vitro evaluation of 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives. (2015) (0)
Pain control between cannabinoid and vanilloid receptors: cooperations and counteractions (2011) (0)
P17.2 Relationship among the endocannabinoid system, atherosclerosis and cognitive status (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Vincenzo Di Marzo?

Vincenzo Di Marzo is affiliated with the following schools:

University of Bonn
Université Laval
University of Calgary
University of Salerno
Imperial College London
University of Eastern Piedmont
University of Siena
University of Washington
University of Naples Federico II